[go: up one dir, main page]

HUT65548A - Process for resolvation of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane and pharmateutical preparations containing it - Google Patents

Process for resolvation of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane and pharmateutical preparations containing it

Info

Publication number
HUT65548A
HUT65548A HU9302377A HU9302377A HUT65548A HU T65548 A HUT65548 A HU T65548A HU 9302377 A HU9302377 A HU 9302377A HU 9302377 A HU9302377 A HU 9302377A HU T65548 A HUT65548 A HU T65548A
Authority
HU
Hungary
Prior art keywords
oxathiolane
hydroxymethyl
pharmateutical
fluorocytosin
resolvation
Prior art date
Application number
HU9302377A
Other languages
English (en)
Other versions
HU9302377D0 (en
HU227823B1 (en
Inventor
Dennis Casey Liotta
Raymond F Schinazi
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT65548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Univ Emory filed Critical Univ Emory
Publication of HU9302377D0 publication Critical patent/HU9302377D0/hu
Publication of HUT65548A publication Critical patent/HUT65548A/hu
Publication of HU227823B1 publication Critical patent/HU227823B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU9302377A 1991-02-22 1992-02-20 Pharmaceutical compositions comprising 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane and further antiviral agent HU227823B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US73608991A 1991-07-26 1991-07-26
US83115392A 1992-02-12 1992-02-12
PCT/US1992/001339 WO1992014743A2 (en) 1991-02-22 1992-02-20 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Publications (3)

Publication Number Publication Date
HU9302377D0 HU9302377D0 (en) 1993-11-29
HUT65548A true HUT65548A (en) 1994-06-28
HU227823B1 HU227823B1 (en) 2012-03-28

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9302377A HU227823B1 (en) 1991-02-22 1992-02-20 Pharmaceutical compositions comprising 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane and further antiviral agent
HU95P/P00510P HU211344A9 (en) 1991-02-22 1995-06-28 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU95P/P00510P HU211344A9 (en) 1991-02-22 1995-06-28 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Country Status (25)

Country Link
EP (3) EP0984013B1 (hu)
JP (2) JP2901160B2 (hu)
KR (1) KR0172590B1 (hu)
CN (4) CN1037682C (hu)
AT (2) ATE270291T1 (hu)
AU (2) AU679649B2 (hu)
BG (1) BG62053B1 (hu)
BR (1) BR9205661A (hu)
CA (2) CA2104399C (hu)
CZ (1) CZ295074B6 (hu)
DE (2) DE69233786D1 (hu)
DK (2) DK1439177T3 (hu)
ES (2) ES2345102T3 (hu)
FI (2) FI114915B (hu)
HK (1) HK1026419A1 (hu)
HU (2) HU227823B1 (hu)
IE (1) IE920545A1 (hu)
IL (1) IL100965A (hu)
MX (1) MX9200747A (hu)
MY (1) MY114350A (hu)
NO (3) NO312399B1 (hu)
NZ (2) NZ241625A (hu)
PT (1) PT100151B (hu)
RO (2) RO122814B1 (hu)
WO (1) WO1992014743A2 (hu)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
EP0831852B1 (en) * 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
DE69727240T2 (de) 1996-06-25 2004-11-25 Glaxo Group Ltd., Greenford Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO1998041522A1 (en) * 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
WO1998044913A2 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
WO1999037754A2 (en) * 1998-01-26 1999-07-29 Pharm-Eco Laboratories, Inc. Enzyme activated supports for enantiomeric separations
JP2002504558A (ja) 1998-02-25 2002-02-12 エモリー ユニバーシテイ ２’−フルオロヌクレオシド
PT1104415E (pt) 1998-08-12 2005-03-31 Univ Emory Metodo de preparacao de nucleosidos de 1,3-oxatiolano
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2209532T3 (es) 1998-12-23 2004-06-16 Shire Biochem Inc. Analogos de nucleosidos antivirales.
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
ATE420972T1 (de) * 2002-11-18 2009-01-15 Shire Biochem Inc Stereoselektiver prozess zur herstellung von nukleosidanalogen dioxolan-derivaten
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
ES2446102T3 (es) * 2005-03-14 2014-03-06 Shire Canada Inc. Proceso y procedimientos para la preparación de cis-2-hidroximetil-4-(citosin-1-il)-1,3-oxatiolano ópticamente activo o sales farmacéuticamente aceptables del mismo
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
WO2009084033A2 (en) 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
EP2258709A1 (en) 2008-02-29 2010-12-08 Kaneka Corporation 2'-hydroxyl-protected ribonucleoside derivative and manufacturing method of same
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022011554A1 (zh) * 2020-07-14 2022-01-20 四川大学 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DE69122264T2 (de) * 1990-11-13 1997-02-06 Biochem Pharma Inc., Laval, Quebec Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
CA2105486C (en) 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides

Also Published As

Publication number Publication date
NO932980D0 (no) 1993-08-20
JPH10147586A (ja) 1998-06-02
HU9302377D0 (en) 1993-11-29
HU211344A9 (en) 1995-11-28
CN100396785C (zh) 2008-06-25
DK0984013T3 (da) 2004-10-25
NO932980L (no) 1993-08-20
NO2005015I1 (no) 2005-07-11
CA2104399C (en) 2005-10-18
AU665187B2 (en) 1995-12-21
IE920545A1 (en) 1992-08-26
EP0984013B1 (en) 2004-06-30
IL100965A (en) 1999-12-31
RO122814B1 (ro) 2010-02-26
ES2345102T3 (es) 2010-09-15
WO1992014743A3 (en) 1992-10-29
ATE469147T1 (de) 2010-06-15
CN1418966A (zh) 2003-05-21
NO2008010I1 (no) 2008-07-07
JP2901160B2 (ja) 1999-06-07
MY114350A (en) 2002-10-31
DE69233379T2 (de) 2005-07-14
EP0984013A3 (en) 2000-08-02
CZ295074B6 (cs) 2005-05-18
CN1084745C (zh) 2002-05-15
CN1109108C (zh) 2003-05-21
CZ49792A3 (en) 1993-03-17
EP1439177B1 (en) 2010-05-26
CA2513440A1 (en) 1992-09-03
BG98062A (bg) 1994-04-29
BG62053B1 (bg) 1999-01-29
JP3292830B2 (ja) 2002-06-17
PT100151A (pt) 1993-05-31
DE69233786D1 (de) 2010-07-08
HK1026419A1 (en) 2000-12-15
CN1127301A (zh) 1996-07-24
NO312399B1 (no) 2002-05-06
EP0575482A1 (en) 1993-12-29
EP0984013A2 (en) 2000-03-08
FI933684L (fi) 1993-09-06
NZ250842A (en) 1996-03-26
CA2104399A1 (en) 1992-08-23
CN1203232A (zh) 1998-12-30
KR0172590B1 (ko) 1999-02-01
FI20030932A (fi) 2003-06-24
CN1037682C (zh) 1998-03-11
JPH06508605A (ja) 1994-09-29
MX9200747A (es) 1992-09-01
IL100965A0 (en) 1992-11-15
EP1439177A1 (en) 2004-07-21
DE69233379D1 (de) 2004-08-05
RO119365B1 (ro) 2004-08-30
CA2513440C (en) 2010-11-30
AU3794395A (en) 1996-03-14
AU1561792A (en) 1992-09-15
FI114915B (fi) 2005-01-31
WO1992014743A2 (en) 1992-09-03
HU227823B1 (en) 2012-03-28
BR9205661A (pt) 1994-05-24
DK1439177T3 (da) 2010-08-02
AU8077398A (en) 1998-10-15
ES2224547T3 (es) 2005-03-01
FI933684A0 (fi) 1993-08-20
NO2005015I2 (no) 2007-10-01
ATE270291T1 (de) 2004-07-15
NZ241625A (en) 1996-03-26
AU679649B2 (en) 1997-07-03
PT100151B (pt) 1999-09-30
CN1065065A (zh) 1992-10-07

Similar Documents

Publication Publication Date Title
HUT65548A (en) Process for resolvation of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane and pharmateutical preparations containing it
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
IL101836A (en) Pharmaceutical compositions containing 1, 3-oxathiolane nucleoside analogues
FI20050672L (fi) Menetelmä terapeuttisesti käyttökelpoisen Beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin valmistamiseksi
MY109796A (en) 1,3-oxathiolane nucleoside analogues.
DE69232649D1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
AR021811A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de gmpc fosfodiesterasa y las composiciones farmaceuticas que las contienen.
ATE214066T1 (de) Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
IL101932A0 (en) Processes for the diastereoselective synthesis of oxathiolane,dioxolane and dithiolane derivatives,and oxathiolane and dioxolane derivatives for use therein
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
DK224286D0 (da) 2',3'-dideoxy-nucleosider
SI1095042T1 (sl) Antiparazitski artemizininski derivati
NZ232421A (en) Purine or pyrimidine substituted 1,3-oxathiolane derivatives; preparatory process, intermediates and pharmaceutical compositions
MX9203320A (es) Composicion antialergica que contiene compuestos biciclicos switterionicos.
HUT50465A (en) Process for producing amino-alkyl-substituted heterocyclic sulfur-compounds and pharmaceutical compositions containing them as active components
UA37251C2 (uk) Лікарський засіб для лікування або профілактики вірусної інфекції гепатиту в і спосіб лікування вірусної інфекції гепатиту в
RU93058540A (ru) Производные 2-гидроксиметил-5-/5-фторцитозин-1-ил/-1,3-оксатиолан, фармкомпозиция, способы его получения, применение, способы лечения
ATE28457T1 (de) (5-(2-aminomethyl-imidazol-1-yl)-1,3-dialkyl-1h pyrazol-4-yl)(aryl)methanone und verfahren zu deren herstellung.

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: EMTRICITABINE AND TENOFOVIR-DIZOPROXIL; REG. NO/DATE: EU/1/04/305/001 20050221

Spc suppl protection certif: S1200017

Filing date: 20120823

Expiry date: 20120220

Free format text: PRODUCT NAME: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR-DIZOPROXIL; REG. NO/DATE: EU/1/07/430/001 20071213

Spc suppl protection certif: S1200018

Filing date: 20120823

Expiry date: 20120220